🇺🇸 FDA

Company profile · Sponsor

Cyclerion

Cyclerion Therapeutics

CYCN · NYSE pharma CAMBRIDGE, MA, USA
Pipeline
9
Drugs
0
Patents
8

Quick answer

Cyclerion (CYCN) is a pharma company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker CYCN
Exchange NYSE
Company type pharma
Headquarters CAMBRIDGE, MA, USA
SEC CIK 0001755237

Pipeline (9)

Search pipeline →

  1. IW-1701

    Cyclerion

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  2. IW-1973

    Cyclerion

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  3. Matching Placebo

    Cyclerion

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  4. Olinciguat

    Cyclerion

    Achalasia

    phase 2 small molecule terminated

    1 trial

  5. IW-1701

    Cyclerion

    Healthy

    phase 1 small molecule completed

    2 trials

  6. IW-1973

    Cyclerion

    Healthy

    phase 1 small molecule completed

    2 trials

  7. Olinciguat

    Cyclerion

    Healthy

    phase 1 small molecule completed

    1 trial

  8. [14C]-olinciguat

    Cyclerion

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. [14C]-praliciguat

    Cyclerion

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12247025

    Processes for preparation of soluble guanylate cyclase stimulators

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11834444

    Processes for preparation of soluble guanylate cyclase stimulators

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11731977

    SGC stimulators

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11690828

    Treatment of CNS diseases with sGC stimulators

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11572358

    Solid forms of an sGC stimulator

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11466015

    Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11389449

    Treatment of metabolic syndrome with an sGC stimulator

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11357777

    Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Cyclerion?

Cyclerion (CYCN) is a pharma company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Cyclerion sponsor?

We track 9 ClinicalTrials.gov-linked programs for Cyclerion, including IW-1701 and 8 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Cyclerion company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.